Toxicology studies with cytembena (NSC-104801), an antineoplastic agent with a multispecies nephrotoxic effect.

Cancer chemotherapy reports Pub Date : 1975-11-01
E J Gralla, G L Coleman, G W Osbaldiston, M Kashgarian, A M Jonas
{"title":"Toxicology studies with cytembena (NSC-104801), an antineoplastic agent with a multispecies nephrotoxic effect.","authors":"E J Gralla,&nbsp;G L Coleman,&nbsp;G W Osbaldiston,&nbsp;M Kashgarian,&nbsp;A M Jonas","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The toxic effects of cytembena in beagle dogs and rhesus monkeys were investigated with the drug given as single or daily iv injections in doses ranging from 12.5 to 200 mg/kg/day to dogs and 6.25 to 50 mg/kg/day to monkeys. Renal tubular damage was a major drug- and dose-related finding in both species and was clinically indicated by an accompanying uremia, elevated serum creatinine, and proteinuria. In the kidney, the primary lesion was cellular necrosis and desquamation of the distal tubular epithelium in animals given the lowest toxic doses. More severe but similar histologic changes produced by this drug were further characterized by single dose studies in mice which showed renal mitochondrial swelling and disruption plus generalized cell swelling as progressive, subcellular developments which were well established 24 hours after treatment. Cellular regeneration in the renal tubular epithelium was found in dogs and monkeys retained 6 weeks for observation after treatment, although functional recovery was inconsistent. A toxic effect to lymphoid tissue was an additional finding which is described.</p>","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 6","pages":"1071-81"},"PeriodicalIF":0.0000,"publicationDate":"1975-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer chemotherapy reports","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The toxic effects of cytembena in beagle dogs and rhesus monkeys were investigated with the drug given as single or daily iv injections in doses ranging from 12.5 to 200 mg/kg/day to dogs and 6.25 to 50 mg/kg/day to monkeys. Renal tubular damage was a major drug- and dose-related finding in both species and was clinically indicated by an accompanying uremia, elevated serum creatinine, and proteinuria. In the kidney, the primary lesion was cellular necrosis and desquamation of the distal tubular epithelium in animals given the lowest toxic doses. More severe but similar histologic changes produced by this drug were further characterized by single dose studies in mice which showed renal mitochondrial swelling and disruption plus generalized cell swelling as progressive, subcellular developments which were well established 24 hours after treatment. Cellular regeneration in the renal tubular epithelium was found in dogs and monkeys retained 6 weeks for observation after treatment, although functional recovery was inconsistent. A toxic effect to lymphoid tissue was an additional finding which is described.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
具有多物种肾毒性作用的抗肿瘤药物cytembena (NSC-104801)的毒理学研究。
本研究以单次或每日静脉注射的方式研究了小猎犬犬和恒河猴的毒作用,注射剂量为12.5 - 200mg /kg/天,注射剂量为6.25 - 50mg /kg/天。肾小管损害是两个物种中主要的药物和剂量相关发现,临床表现为尿毒症、血清肌酐升高和蛋白尿。在肾脏中,给予最低毒性剂量的动物的原发性病变是细胞坏死和远端小管上皮脱屑。单剂量小鼠研究进一步表明,该药产生的更严重但类似的组织学变化,显示肾线粒体肿胀和破坏以及全身细胞肿胀,这是治疗后24小时建立的进行性亚细胞发育。狗和猴子在治疗后保留6周观察时发现肾小管上皮细胞再生,但功能恢复不一致。对淋巴组织的毒性作用是另一项发现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
PORFIROMYCIN. Phase I study of 5-azacytidine (NSC-102816) using 24-hour continuous infusion for 5 days. Bleomycin (NSC-125066) and CCNU (NSC-79037) in the combination chemotherapy of mopp-resistant hodgkin's disease. Combination chemotherapy with 5-fluorouracil (NSC-19893), methotrexate (NSC-740), and prednisolone (NSC-9900) (FAP protocol) for hepatoma. Cyclophosphamide (NSC-26271) maintenance therapy after a second remission of childhood acute lymphoblastic leukemia: comparative clinical trial (standard dose versus intermittent high dose versus cyclophosphamide plus cytosine arabinoside (NSC-63878)).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1